Notably, according to both the univariate and multivariate analyses, ER status, PR status, CA125 level, histologic grade, and the type of adjuvant therapy did not affect PFS or OS in FIGO stage I endometrial cancer patients in our study, but age was associated with differences in OS and PFS. The gene discussed is MUC16; the disease is endometrial cancer.